Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending October 7, 2018

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251

auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489

Low arginine linked to SFTS, Li X-K et al. Sci Transl Med. doi: 10.1126/scitranslmed.aat4162

More must reads

Must reads for theWeek ending September 23, 2018

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

More must reads

Must reads for theWeek ending September 2, 2018

Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

ctDNA may predict survival, treatment response in DLBCL, Kurtz DM et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.78.5246.

Post-discharge rivaroxaban does not change VTE risk, Spyropoulos AC et al. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1805090.

Restrictive transfusion strategy in CV surgery doesn't raise long-term risk, Mazer CD et al. N Engl J Med. 2018 Aug 26. doi:10.1056/NEJMoa1808561

Promise of SGN-CD70A against NHL eclipsed by adverse events, Phillips T et al. Invest New Drugs. 2018 Aug 22. doi: 10.1007/s10637-018-0655-0.

More must reads

Must reads for theWeek ending August 26, 2018

Rituximab maintenance leads to better MCL outcomes, Vidal L et al. HemaSphere. 2018 Aug;2(4):e136.

CBC outperforms D-dimer in predicting DVT, The annual meeting of the American College of Physicians

Multidisciplinary care shortens hospital stay in sickle cell disease, Annual symposium of the Foundation for Sickle Cell Disease Research

CAR T signaling strength analyzed in preclinical study, Salter AI et al., Sci Signal. 2018 Aug 21;11. pii:eaat6753.

Obinutuzumab plus venetoclax compares well with established CLL therapies, Cramer P et al. Lancet Oncol. 2018 Aug 13. doi: 10.1016/S1470-2045(18)30414-5.

More must reads

Must reads for theWeek ending August 19, 2018

Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA

Cleveland institutions to study CAR-T in Non-Hodgkin lymphoma, University Hospitals Cleveland Medical Center press statement

Caution urged over real-world bleeding risk with ibrutinib, Kunk PR et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 15. doi: 10.1016/j.clml.2018.07.287

More must reads

Pages